CTLA4 Human, Sf9

Cytotoxic T-Lymphocyte Associated Antigen-4 Human Recombinant, Sf9
Cat. No.
BT20596
Source
Sf9, Baculovirus cells.
Synonyms
Cytotoxic T-Lymphocyte Associated Protein 4, Cytotoxic T-Lymphocyte-Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Celiac Disease 3, CTLA-4, CD152, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4, GSE, CD, Cytotoxic T-lymphocyte protein 4, CTLA4.
Appearance
Sterile filtered colorless solution.
Purity
Greater than 90% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

CTLA4 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 135 amino acids (36-161a.a.) and having a molecular mass of 14.6kDa (Molecular size on SDS-PAGE will appear at approximately 18-28kDa).
CTLA4 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
CTLA-4, a protein belonging to the immunoglobulin superfamily, plays a crucial role in regulating immune responses by delivering inhibitory signals to T cells. This protein comprises various domains: a V domain, a transmembrane domain, and a cytoplasmic tail. Notably, alternative splicing of the CTLA-4 gene leads to the production of multiple isoforms with distinct characteristics. While the membrane-bound isoform forms homodimers through disulfide bonds, the soluble isoform exists as a monomer. Genetic mutations affecting CTLA-4 have been implicated in a range of autoimmune disorders, including insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, and thyroid-associated orbitopathy.
Description
Recombinant CTLA4 protein, expressed in Sf9 insect cells using a baculovirus system, is a single, glycosylated polypeptide chain. It encompasses 135 amino acids (residues 36-161) and possesses a molecular weight of 14.6 kDa. On SDS-PAGE, the protein's apparent molecular size ranges from approximately 18 to 28 kDa. This CTLA4 variant features a 6-amino acid His tag at its C-terminus, facilitating purification via proprietary chromatographic methods.
Physical Appearance
The product appears as a clear, colorless liquid that has been sterilized by filtration.
Formulation
The CTLA4 protein is provided as a solution at a concentration of 0.25 mg/ml. The formulation buffer consists of Phosphate Buffered Saline (pH 7.4) and 20% glycerol.
Stability
For short-term storage (up to 2-4 weeks), maintain the product at 4°C. For prolonged storage, store the protein at -20°C. It is advisable to add a carrier protein, such as 0.1% HSA or BSA, for long-term storage to enhance stability. To preserve protein integrity, minimize repeated freeze-thaw cycles.
Purity
The purity of the CTLA4 protein is determined to be greater than 90% based on SDS-PAGE analysis.
Biological Activity
The biological activity of CTLA4 is assessed by measuring its ability to inhibit IL-2 production in Jurkat human acute T cell leukemia cells using an IL-2 ELISA. The ED50, representing the concentration at which 50% inhibition is observed, is typically within the range of ≤ 150 ng/ml when tested with Human B7-1/CD80.
Synonyms
Cytotoxic T-Lymphocyte Associated Protein 4, Cytotoxic T-Lymphocyte-Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Celiac Disease 3, CTLA-4, CD152, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4, GSE, CD, Cytotoxic T-lymphocyte protein 4, CTLA4.
Source
Sf9, Baculovirus cells.
Amino Acid Sequence
ADLKAMHVAQ PAVVLASSRG IASFVCEYAS PGKATEVRVT VLRQADSQVT EVCAATYMMG NELTFLDDSI CTGTSSGNQV NLTIQGLRAM DTGLYICKVE LMYPPPYYLG IGNGTQIYVI DPEPCPDSDH HHHHH.

Product Science Overview

Introduction

Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4), also known as CD152, is a critical immune checkpoint molecule that plays a pivotal role in regulating immune responses. It is predominantly expressed on the surface of activated T cells and regulatory T cells (Tregs). The recombinant form of CTLA-4, produced in Sf9 insect cells, is utilized in various research and therapeutic applications.

Structure and Function

CTLA-4 is a single-chain transmembrane glycoprotein that shares structural similarities with the co-stimulatory molecule CD28. Both CTLA-4 and CD28 bind to the B7 family molecules (CD80/CD86) on antigen-presenting cells (APCs), but with opposing effects. While CD28 promotes T cell activation and proliferation, CTLA-4 acts as a negative regulator, dampening T cell responses and maintaining immune homeostasis .

Mechanism of Action

CTLA-4 competes with CD28 for binding to CD80/CD86 with higher affinity, thereby inhibiting the co-stimulatory signals required for full T cell activation. This competitive inhibition is crucial for preventing overactivation of the immune system, which can lead to autoimmunity . In addition to its role in T cells, CTLA-4 has been shown to modulate B cell responses, particularly in the context of autoimmune diseases .

Therapeutic Applications

The immunoregulatory properties of CTLA-4 have made it an attractive target for therapeutic interventions, particularly in cancer and autoimmune diseases. CTLA-4-Ig, a fusion protein combining the extracellular domain of CTLA-4 with the Fc region of IgG1, has been developed to inhibit T cell activation by blocking CD80/CD86 interactions. This therapeutic approach has shown efficacy in treating conditions such as rheumatoid arthritis and has been explored in cancer immunotherapy .

CTLA-4 in Tumor Immunity

CTLA-4 plays a significant role in tumor immunity by modulating T cell responses within the tumor microenvironment. Tumor cells often exploit immune checkpoint molecules like CTLA-4 to evade immune detection and destruction. By inhibiting CTLA-4, immune checkpoint inhibitors can restore T cell activity and enhance anti-tumor immune responses. This has led to the development of monoclonal antibodies targeting CTLA-4, which have demonstrated clinical benefits in various malignancies, including melanoma and renal cell carcinoma .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

CTLA4 Antibody
Cytotoxic T-Lymphocyte Associated Antigen-4, Mouse Anti Human
Cat. No.
BT4343
Source
CTLA 4 Human
Cytotoxic T-Lymphocyte Associated Antigen-4 Human Recombinant
Cat. No.
BT20253
Source
Escherichia Coli.
CTLA4 Human, igG-His
Cytotoxic T-Lymphocyte Associated Antigen-4 Human Recombinant, igG-His Tag
Cat. No.
BT20411
Source
Sf9, Baculovirus cells.
CTLA4 Mouse
Cytotoxic T-Lymphocyte Associated Antigen-4 Mouse Recombinant
Cat. No.
BT20679
Source
Sf9 Insect cells.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.